1
|
Girish A, Jolly K, Alsaadi N, de la Fuente M, Recchione A, An R, Disharoon D, Secunda Z, Raghunathan S, Luc NF, Desai C, Knauss E, Han X, Hu K, Wang H, Sekhon UDS, Rohner N, Gurkan UA, Nieman M, Neal MD, Sen Gupta A. Platelet-Inspired Intravenous Nanomedicine for Injury-Targeted Direct Delivery of Thrombin to Augment Hemostasis in Coagulopathies. ACS NANO 2022; 16:16292-16313. [PMID: 35916497 PMCID: PMC10195184 DOI: 10.1021/acsnano.2c05306] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]
Abstract
Severe hemorrhage associated with trauma, surgery, and congenital or drug-induced coagulopathies can be life-threatening and requires rapid hemostatic management via topical, intracavitary, or intravenous routes. For injuries that are not easily accessible externally, intravenous hemostatic approaches are needed. The clinical gold standard for this is transfusion of blood products, but due to donor dependence, specialized storage requirements, high risk of contamination, and short shelf life, blood product use faces significant challenges. Consequently, recent research efforts are being focused on designing biosynthetic intravenous hemostats, using intravenous nanoparticles and polymer systems. Here we report on the design and evaluation of thrombin-loaded injury-site-targeted lipid nanoparticles (t-TLNPs) that can specifically localize at an injury site via platelet-mimetic anchorage to the von Willebrand factor (vWF) and collagen and directly release thrombin via diffusion and phospholipase-triggered particle destabilization, which can locally augment fibrin generation from fibrinogen for hemostatic action. We evaluated t-TLNPs in vitro in human blood and plasma, where hemostatic defects were created by platelet depletion and anticoagulation. Spectrophotometric studies of fibrin generation, rotational thromboelastometry (ROTEM)-based studies of clot viscoelasticity, and BioFlux-based real-time imaging of fibrin generation under simulated vascular flow conditions confirmed that t-TLNPs can restore fibrin in hemostatic dysfunction settings. Finally, the in vivo feasibility of t-TLNPs was tested by prophylactic administration in a tail-clip model and emergency administration in a liver-laceration model in mice with induced hemostatic defects. Treatment with t-TLNPs was able to significantly reduce bleeding in both models. Our studies demonstrate an intravenous nanomedicine approach for injury-site-targeted direct delivery of thrombin to augment hemostasis.
Collapse
Affiliation(s)
- Aditya Girish
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Ketan Jolly
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Nijmeh Alsaadi
- Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15123, United States
| | - Maria de la Fuente
- Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Arielle Recchione
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Ran An
- Department of Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Dante Disharoon
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Zachary Secunda
- Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15123, United States
| | - Shruti Raghunathan
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Norman F Luc
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Cian Desai
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Elizabeth Knauss
- Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Xu Han
- Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Keren Hu
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Hanyang Wang
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Ujjal Didar Singh Sekhon
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Nathan Rohner
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Umut A Gurkan
- Department of Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Marvin Nieman
- Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Matthew D Neal
- Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15123, United States
| | - Anirban Sen Gupta
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
- Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106, United States
| |
Collapse
|
2
|
Ding WY, Protty MB, Davies IG, Lip GYH. Relationship between lipoproteins, thrombosis and atrial fibrillation. Cardiovasc Res 2021; 118:716-731. [PMID: 33483737 PMCID: PMC8859639 DOI: 10.1093/cvr/cvab017] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Revised: 12/14/2020] [Accepted: 01/12/2021] [Indexed: 12/19/2022] Open
Abstract
The prothrombotic state in atrial fibrillation (AF) occurs as a result of multifaceted interactions, known as Virchow’s triad of hypercoagulability, structural abnormalities, and blood stasis. More recently, there is emerging evidence that lipoproteins are implicated in this process, beyond their traditional role in atherosclerosis. In this review, we provide an overview of the various lipoproteins and explore the association between lipoproteins and AF, the effects of lipoproteins on haemostasis, and the potential contribution of lipoproteins to thrombogenesis in AF. There are several types of lipoproteins based on size, lipid composition, and apolipoprotein category, namely: chylomicrons, very low-density lipoprotein, low-density lipoprotein (LDL), intermediate-density lipoprotein, and high-density lipoprotein. Each of these lipoproteins may contain numerous lipid species and proteins with a variety of different functions. Furthermore, the lipoprotein particles may be oxidized causing an alteration in their structure and content. Of note, there is a paradoxical inverse relationship between total cholesterol and LDL cholesterol (LDL-C) levels, and incident AF. The mechanism by which this occurs may be related to the stabilizing effect of cholesterol on myocardial membranes, along with its role in inflammation. Overall, specific lipoproteins may interact with haemostatic pathways to promote excess platelet activation and thrombin generation, as well as inhibiting fibrinolysis. In this regard, LDL-C has been shown to be an independent risk factor for thromboembolic events in AF. The complex relationship between lipoproteins, thrombosis and AF warrants further research with an aim to improve our knowledge base and contribute to our overall understanding of lipoprotein-mediated thrombosis.
Collapse
Affiliation(s)
- Wern Yew Ding
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
| | - Majd B Protty
- Systems Immunity University Research Institute, Cardiff University, Cardiff, United Kingdom
| | - Ian G Davies
- Research Institute of Sport and Exercise Science, Liverpool John Moores University, Liverpool, United Kingdom
| | - Gregory Y H Lip
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.,Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| |
Collapse
|
3
|
Group IIA Secretory Phospholipase A2 Predicts Graft Failure and Mortality in Renal Transplant Recipients by Mediating Decreased Kidney Function. J Clin Med 2020; 9:jcm9051282. [PMID: 32365505 PMCID: PMC7288094 DOI: 10.3390/jcm9051282] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Revised: 04/24/2020] [Accepted: 04/25/2020] [Indexed: 01/14/2023] Open
Abstract
The acute phase protein group IIA secretory phospholipase A2 (sPLA2-IIA) has intrinsic proatherosclerotic properties. The present prospective cohort study investigated whether plasma sPLA2-IIA associates with graft failure, cardiovascular, and all-cause mortality in renal transplant recipients (RTRs), patients with accelerated atherosclerosis formation both systemically and within the graft. In 511 RTRs from a single academic center with stable graft function >1 year, baseline plasma sPLA2-IIA was determined by ELISA. Primary end points were death-censored graft failure and mortality (median follow-up, 7.0 years). Baseline sPLA2-IIA was higher in RTRs than in healthy controls (median 384 ng/dL (range 86–6951) vs. 185 ng/dL (range 104–271), p < 0.001). Kaplan–Meier analysis demonstrated increased risk for graft failure (p = 0.002), as well as cardiovascular (p < 0.001) and all-cause mortality (p < 0.001), with increasing sPLA2-IIA quartiles. Cox regression showed strong associations of sPLA2-IIA with increased risks of graft failure (hazard ratio (HR) = 1.42 (1.11–1.83), p = 0.006), as well as cardiovascular (HR = 1.48 (1.18−1.85), p = 0.001) and all-cause mortality (HR = 1.39 (1.17−1.64), p < 0.001), dependent on parameters of kidney function. Renal function during follow-up declined faster in RTRs with higher baseline sPLA2-IIA levels. In RTRs, sPLA2-IIA is a significant predictive biomarker for chronic graft failure, as well as overall and cardiovascular disease mortality dependent on kidney function. This dependency is conceivably explained by sPLA2-IIA impacting negatively on kidney function.
Collapse
|
4
|
Elia E, Montecucco F, Portincasa P, Sahebkar A, Mollazadeh H, Carbone F. Update on pathological platelet activation in coronary thrombosis. J Cell Physiol 2018; 234:2121-2133. [PMID: 30317596 DOI: 10.1002/jcp.27575] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2018] [Accepted: 09/17/2018] [Indexed: 12/19/2022]
Abstract
Although coronary thrombosis (CT) is integral to cardiovascular outcomes, the underlying pathophysiological mechanisms remain unclear. CT may occur in case of atherosclerotic plaque erosion/rupture, or even after stenting implantation. Platelets (PLT) activation is the keystone of atherothrombosis and depends on many dysregulated elements, including endothelial dysfunction, oxidized lipoproteins, and immune response. Besides the classical view of PLT as an effector of hemostatic response, a new repertoire of PLT activities is emerging. PLT lipidome oxidation is a self-maintaining process which promotes PLT reactivity, coagulation cascade, and inflammatory cell activation. PLT-innate immune cell interaction is also sustained by neutrophil extracellular traps and NLRP3 inflammasome pathways. Other noteworthy emerging mechanisms are implicated in the crosstalk between PLT and surrounding cells. Especially, microvesicles (MVs) released from PLT may extend their signaling network far beyond the classical cell-cell interactions. Moreover, the recognition of noncoding RNA in PLT MVs introduce another layer of complexity in terms of intercellular signaling by a direct regulation of messenger RNA profile and gene expression in the recipient cells. The aim of this narrative review is to update the recent advance in CT and intracoronary stent thrombosis, including causal factors and potential translation of experimental evidence into the clinical setting.
Collapse
Affiliation(s)
- Edoardo Elia
- Department of Internal Medicine, First Clinic of Internal Medicine, University of Genoa, Genoa, Italy
| | - Fabrizio Montecucco
- Department of Internal Medicine, First Clinic of Internal Medicine, University of Genoa, Genoa, Italy.,Department of Internal Medicine, First Clinic of Internal Medicine, Ospedale Policlinico San Martino, 10 Largo Benzi, Genoa, Italy.,Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy
| | - Piero Portincasa
- Department of Biomedical Sciences and Human Oncology, Clinica Medica "A. Murri," University of Bari Medical School, Bari, Italy
| | - Amirhossein Sahebkar
- Department of Pharmaceutical Biotechnology, Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.,Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.,School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Hamid Mollazadeh
- Department of Physiology and Pharmacology, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
| | - Federico Carbone
- Department of Internal Medicine, First Clinic of Internal Medicine, University of Genoa, Genoa, Italy
| |
Collapse
|
5
|
Obermayer G, Afonyushkin T, Binder CJ. Oxidized low-density lipoprotein in inflammation-driven thrombosis. J Thromb Haemost 2018; 16:418-428. [PMID: 29316215 DOI: 10.1111/jth.13925] [Citation(s) in RCA: 56] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Thrombosis is the defining feature of the most prevalent causes of cardiovascular mortality, such as myocardial infarction, stroke, and pulmonary artery embolism. Although platelet activation and activation of the plasmatic coagulation system are the hallmarks of thrombus formation, inflammatory processes and the cellular responses involved are increasingly being recognized as critical modulators of thrombosis. In the context of many chronic inflammatory diseases that are associated with a high thrombotic risk, oxidized lipoproteins represent a prominent sterile trigger of inflammation. Oxidized low-density lipoprotein and its components play a central role in the initiation and progression of atherosclerotic plaques, but also in other processes that lead to thrombotic events. Moreover, dying cells and microvesicles can be decorated with some of the same oxidized lipid components that are found on oxidized lipoproteins, and thereby similar mechanisms of thromboinflammation may also be active in venous thrombosis. In this review, we summarize the current knowledge on how oxidized lipoproteins and components thereof affect the cells and pathways involved in thrombosis.
Collapse
Affiliation(s)
- G Obermayer
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
- Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
| | - T Afonyushkin
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
- Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
| | - C J Binder
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
- Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
| |
Collapse
|
6
|
Woudberg NJ, Pedretti S, Lecour S, Schulz R, Vuilleumier N, James RW, Frias MA. Pharmacological Intervention to Modulate HDL: What Do We Target? Front Pharmacol 2018; 8:989. [PMID: 29403378 PMCID: PMC5786575 DOI: 10.3389/fphar.2017.00989] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2017] [Accepted: 12/22/2017] [Indexed: 12/24/2022] Open
Abstract
The cholesterol concentrations of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) have traditionally served as risk factors for cardiovascular disease. As such, novel therapeutic interventions aiming to raise HDL cholesterol have been tested in the clinical setting. However, most trials led to a significant increase in HDL cholesterol with no improvement in cardiovascular events. The complexity of the HDL particle, which exerts multiple physiological functions and is comprised of a number of subclasses, has raised the question as to whether there should be more focus on HDL subclass and function rather than cholesterol quantity. We review current data regarding HDL subclasses and subclass-specific functionality and highlight how current lipid modifying drugs such as statins, cholesteryl ester transfer protein inhibitors, fibrates and niacin often increase cholesterol concentrations of specific HDL subclasses. In addition this review sets out arguments suggesting that the HDL3 subclass may provide better protective effects than HDL2.
Collapse
Affiliation(s)
- Nicholas J. Woudberg
- Hatter Institute for Cardiovascular Research in Africa and South African Medical Research Council Inter-University Cape Heart Group, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - Sarah Pedretti
- Hatter Institute for Cardiovascular Research in Africa and South African Medical Research Council Inter-University Cape Heart Group, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
- Division of Endocrinology, Diabetes, Hypertension and Nutrition, Department of Internal Medicine Specialities, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Sandrine Lecour
- Hatter Institute for Cardiovascular Research in Africa and South African Medical Research Council Inter-University Cape Heart Group, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - Rainer Schulz
- Institute of Physiology, Justus Liebig University Giessen, Giessen, Germany
| | - Nicolas Vuilleumier
- Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
| | - Richard W. James
- Division of Endocrinology, Diabetes, Hypertension and Nutrition, Department of Internal Medicine Specialities, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Miguel A. Frias
- Division of Endocrinology, Diabetes, Hypertension and Nutrition, Department of Internal Medicine Specialities, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
| |
Collapse
|
7
|
De Giorgi M, Enjyoji K, Jiang G, Csizmadia E, Mitsuhashi S, Gumina RJ, Smolenski RT, Robson SC. Complete deletion of Cd39 is atheroprotective in apolipoprotein E-deficient mice. J Lipid Res 2017; 58:1292-1305. [PMID: 28487312 PMCID: PMC5496028 DOI: 10.1194/jlr.m072132] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2016] [Revised: 04/28/2017] [Indexed: 02/07/2023] Open
Abstract
Cd39 scavenges extracellular ATP and ADP, ultimately generating adenosine, a nucleoside, which has anti-inflammatory effects in the vasculature. We have evaluated the role of Cd39 in the development of atherosclerosis in hyperlipidemic mice. ApoE KO (Cd39+/+/ApoE−/−) and Cd39/ApoE double KO (DKO) (Cd39−/−/ApoE−/−) mice were maintained on chow or Western diet for up to 20 weeks before evaluation of atherosclerotic lesions. We found that DKO mice exhibited significantly fewer atherosclerotic lesions than ApoE KO mice, irrespective of diet. Analyses of plaque composition revealed diminished foam cells in the fatty streaks and smaller necrotic cores in advanced lesions of DKO mice, when compared with those in ApoE KO mice. This atheroprotective phenotype was associated with impaired platelet reactivity to ADP in vitro and prolonged platelet survival, suggesting decreased platelet activation in vivo. Further studies with either genetic deletion or pharmacological inhibition of Cd39 in macrophages revealed increased cholesterol efflux mediated via ABCA1 to ApoA1. This phenomenon was associated with elevated plasma HDL levels in DKO mice. Our findings indicate that complete deletion of Cd39 paradoxically attenuates development of atherosclerosis in hyperlipidemic mice. We propose that this phenotype occurs, at least in part, from diminished platelet activation, increased plasma HDL levels, and enhanced cholesterol efflux and indicates the complexity of purinergic signaling in atherosclerosis.
Collapse
Affiliation(s)
- Marco De Giorgi
- Transplant Institute and Hepatology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
| | - Keiichi Enjyoji
- Transplant Institute and Hepatology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
| | - Gordon Jiang
- Transplant Institute and Hepatology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
| | - Eva Csizmadia
- Transplant Institute and Hepatology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
| | - Shuji Mitsuhashi
- Transplant Institute and Hepatology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
| | - Richard J Gumina
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | | | - Simon C Robson
- Transplant Institute and Hepatology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
| |
Collapse
|
8
|
Arora S, Patra SK, Saini R. HDL—A molecule with a multi-faceted role in coronary artery disease. Clin Chim Acta 2016; 452:66-81. [DOI: 10.1016/j.cca.2015.10.021] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2015] [Revised: 10/13/2015] [Accepted: 10/22/2015] [Indexed: 01/18/2023]
|
9
|
Zagol-Ikapite I, Sosa IR, Oram D, Judd A, Amarnath K, Amarnath V, Stec D, Oates JA, Boutaud O. Modification of platelet proteins by malondialdehyde: prevention by dicarbonyl scavengers. J Lipid Res 2015; 56:2196-205. [PMID: 26378094 DOI: 10.1194/jlr.p063271] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2015] [Indexed: 12/25/2022] Open
Abstract
The thromboxane synthase converts prostaglandin H(2) to thromboxane A(2) and malondialdehyde (MDA) in approximately equimolar amounts. A reactive dicarbonyl, MDA forms covalent adducts of amino groups, including the ε-amine of lysine, but the importance of this reaction in platelets was unknown. Utilizing a novel LC/MS/MS method for analysis of one of the MDA adducts, the dilysyl-MDA cross-link, we demonstrated that dilysyl-MDA cross-links in human platelets are formed following platelet activation via the cyclooxygenase (COX)-1/thromboxane synthase pathway. Salicylamine and analogs of salicylamine were shown to react with MDA preferentially, thereby preventing formation of lysine adducts. Dilysyl-MDA cross-links were measured in two diseases known to be associated with increased platelet activation. Levels of platelet dilysyl-MDA cross-links were increased by 2-fold in metabolic syndrome relative to healthy subjects, and by 1.9-fold in sickle cell disease (SCD). In patients with SCD, the reduction of platelet dilysyl-MDA cross-links following administration of nonsteroidal anti-inflammatory drug provided evidence that MDA modifications of platelet proteins in this disease are derived from the COX pathway. In summary, MDA adducts of platelet proteins that cross-link lysines are formed on platelet activation and are increased in diseases associated with platelet activation. These protein modifications can be prevented by salicylamine-related scavengers.
Collapse
Affiliation(s)
| | - Iberia R Sosa
- Department of Medicine, Vanderbilt University, Nashville, TN
| | - Denise Oram
- Department of Medicine, Vanderbilt University, Nashville, TN
| | - Audra Judd
- Department of Medicine, Vanderbilt University, Nashville, TN
| | - Kalyani Amarnath
- Department of Pharmacology, Vanderbilt University, Nashville, TN
| | - Venkataraman Amarnath
- Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN
| | - Donald Stec
- Department of Chemistry, Vanderbilt University, Nashville, TN
| | - John A Oates
- Department of Medicine, Vanderbilt University, Nashville, TN Department of Pharmacology, Vanderbilt University, Nashville, TN
| | - Olivier Boutaud
- Department of Pharmacology, Vanderbilt University, Nashville, TN
| |
Collapse
|
10
|
Kirkby NS, Reed DM, Edin ML, Rauzi F, Mataragka S, Vojnovic I, Bishop-Bailey D, Milne GL, Longhurst H, Zeldin DC, Mitchell JA, Warner TD. Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation. FASEB J 2015; 29:4568-78. [PMID: 26183771 PMCID: PMC4608906 DOI: 10.1096/fj.15-275065] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2015] [Accepted: 07/06/2015] [Indexed: 12/25/2022]
Abstract
Eicosanoids are important vascular regulators, but the phospholipase A2
(PLA2) isoforms supporting their production within the cardiovascular
system are not fully understood. To address this, we have studied platelets,
endothelial cells, and leukocytes from 2 siblings with a homozygous loss-of-function
mutation in group IVA cytosolic phospholipase A2
(cPLA2α). Chromatography/mass spectrometry was used to determine
levels of a broad range of eicosanoids produced by isolated vascular cells, and in
plasma and urine. Eicosanoid release data were paired with studies of cellular
function. Absence of cPLA2α almost abolished eicosanoid synthesis
in platelets (e.g., thromboxane A2, control 20.5 ±
1.4 ng/ml vs. patient 0.1 ng/ml) and leukocytes
[e.g., prostaglandin E2 (PGE2), control
21.9 ± 7.4 ng/ml vs. patient 1.9 ng/ml], and this was
associated with impaired platelet activation and enhanced inflammatory responses.
cPLA2α-deficient endothelial cells showed reduced, but not
absent, formation of prostaglandin I2 (prostacyclin; control 956 ±
422 pg/ml vs. patient 196 pg/ml) and were primed for inflammation.
In the urine, prostaglandin metabolites were selectively influenced by
cPLA2α deficiency. For example, prostacyclin metabolites were
strongly reduced (18.4% of control) in patients lacking cPLA2α,
whereas PGE2 metabolites (77.8% of control) were similar to healthy
volunteer levels. These studies constitute a definitive account, demonstrating the
fundamental role of cPLA2α to eicosanoid formation and cellular
responses within the human circulation.—Kirkby, N. S., Reed, D. M., Edin, M.
L., Rauzi, F., Mataragka, S., Vojnovic, I., Bishop-Bailey, D., Milne, G. L.,
Longhurst, H., Zeldin, D. C., Mitchell, J. A., Warner, T. D. Inherited human group
IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial,
and leucocyte eicosanoid generation.
Collapse
Affiliation(s)
- Nicholas S Kirkby
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Daniel M Reed
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Matthew L Edin
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Francesca Rauzi
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Stefania Mataragka
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Ivana Vojnovic
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - David Bishop-Bailey
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Ginger L Milne
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Hilary Longhurst
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Darryl C Zeldin
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Jane A Mitchell
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Timothy D Warner
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| |
Collapse
|
11
|
Tietge UJ. Extracellular Phospholipases. Atherosclerosis 2015. [DOI: 10.1002/9781118828533.ch23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
12
|
Serban C, Muntean D, Mikhailids DP, Toth PP, Banach M. Dysfunctional HDL: the journey from savior to slayer. ACTA ACUST UNITED AC 2014. [DOI: 10.2217/clp.13.83] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
13
|
Eren E, Yilmaz N, Aydin O. High Density Lipoprotein and it's Dysfunction. Open Biochem J 2012; 6:78-93. [PMID: 22888373 PMCID: PMC3414806 DOI: 10.2174/1874091x01206010078] [Citation(s) in RCA: 114] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2012] [Revised: 04/18/2012] [Accepted: 04/24/2012] [Indexed: 01/22/2023] Open
Abstract
Plasma high-density lipoprotein cholesterol(HDL-C) levels do not predict functionality and composition of high-density lipoprotein(HDL). Traditionally, keeping levels of low-density lipoprotein cholesterol(LDL-C) down and HDL-C up have been the goal of patients to prevent atherosclerosis that can lead to coronary vascular disease(CVD). People think about the HDL present in their cholesterol test, but not about its functional capability. Up to 65% of cardiovascular death cannot be prevented by putative LDL-C lowering agents. It well explains the strong interest in HDL increasing strategies. However, recent studies have questioned the good in using drugs to increase level of HDL. While raising HDL is a theoretically attractive target, the optimal approach remains uncertain. The attention has turned to the quality, rather than the quantity, of HDL-C. An alternative to elevations in HDL involves strategies to enhance HDL functionality. The situation poses an opportunity for clinical chemists to take the lead in the development and validation of such biomarkers. The best known function of HDL is the capacity to promote cellular cholesterol efflux from peripheral cells and deliver cholesterol to the liver for excretion, thereby playing a key role in reverse cholesterol transport (RCT). The functions of HDL that have recently attracted attention include anti-inflammatory and anti-oxidant activities. High antioxidant and anti-inflammatory activities of HDL are associated with protection from CVD.This review addresses the current state of knowledge regarding assays of HDL functions and their relationship to CVD. HDL as a therapeutic target is the new frontier with huge potential for positive public health implications.
Collapse
Affiliation(s)
- Esin Eren
- Antalya Public Health Center of Ministry of Health, Antalya, Turkey
| | | | | |
Collapse
|